The plaintiff, a woman who'd used the company's Panorama test during a pregnancy, is asking the court to certify her case a class action.
The company has signed a deal with Aarhus University that gives it access to a 40,000-sample biobank of patients who were screened for colorectal cancer.
After fighting through some headwinds in 2021, the company said it will show off new data and tests in the next couple of years.
The firm is aiming to create pan-organ transplant services that connect patients to doctors throughout the transplant and recovery process.
The molecular diagnostics company reported $75.6 million in revenues for the quarter and said testing service revenues rose 46 percent year over year.
As Colossal forges ahead with its plans to bring back the woolly mammoth and other extinct species, some have expressed skepticism about its goals.
A new class of transposon-encoded RNA-guided nucleases could be used as biotech tools, and could also reveal new insights on the evolution of CRISPR enzymes.
In a separate case in which CareDx and Natera are suing each other for false advertising, a court has set a trial date in late October.
The New York City-based startup is offering a 20-year-old technology to build new cell lines to the wider scientific community for the first time.
The company, which now ranks as a startup with a valuation of more than $1 billion, will use the new funds to develop CRISPR-based therapeutics.